203 research outputs found

    Comparison of two- and three-dimensional simulations of miscible Rayleigh-Taylor instability

    Get PDF
    A comparison of two-dimensional and three-dimensional high-resolution numerical large-eddy simulations of planar, miscible Rayleigh-Taylor instability flows are presented. The resolution of the three-dimensional simulation is sufficient to attain a fully turbulent state. A number of different statistics from the mixing region (e.g., growth rates, PDFs, mixedness measures, and spectra) are used to demonstrate that two-dimensional flow simulations differ substantially from the three-dimensional one. It is found that the two-dimensional flow grows more quickly than its three-dimensional counterpart at late times, develops larger structures, and is much less well mixed. These findings are consistent with the concept of inverse cascade in two-dimensional flow, as well as the influence of a reduced effective Atwood number on miscible flow

    BCG-INDUCED PRO-INFLAMMATORY PHENOTYPE OF MESENCHYMAL STEM CELLS: EFFECT OF IMMUNE MODULATORS

    Get PDF
    In case of mycobacterial infection the granulomatous infiltration foci contain the significant amount of mesenchymal stem cells (MSC), which functional phenotype and respective function in anti-tuberculosis immune defense remain unknown.Goal of the study: to characterize the MSC phenotype, formed by their interaction with BCG of M. bovis and to evaluate the changes in this phenotype caused by the action of inhibitors and stimulants of immune regulatory action.Materials and methods: MSC retrieved from bone marrow of mice were cultured with the presence and absence of BCG of M. bovis and/or poludanum TLR3 agonist; and the effect of two latter on the production of pro- and anti-inflammatory cytokines was evaluated by enzyme multiplied immunoassay. Flow cytometry and radioactive testing were used to evaluate the impact of cultured BCG fluid and poludanum-conditioned MSC on the proliferative and apoptotic activity of splenocytes. The inhibitors of indoleamine 2,3-dioxygenase (IDO), cyclooxygenase-2 (COG-2) or NO synthase were added to certain cultures alone with BCG and poludanum, and the contributions of IDO, COG-2 and NO to BCG and poludanum-induced response were assessed.Results. Pro-inflammatory polarization of MSC under the action of BCG and poludanum was demonstrated. Pro-inflammatory MSC phenotype correlated to their anti-apoptogenic and growth-stimulating actions on the splenocytes. It was demonstrated that IDO and NO restrained BCG-induced polarization and conversely COG-2 promoted BCG-induced pro-inflammatory polarization of MSC.Conclusions. 1. MSC actively participate in the formation of immunologic anti-mycobacterial resistance. 2. Targeted regulation of IDO and NO production can be feasibly applied for formation of anti-tuberculous vaccinal immunity and control mycobacterial infection

    Π‘Π¦Π–-Π˜ΠΠ”Π£Π¦Π˜Π ΠžΠ’ΠΠΠΠ«Π™ ΠŸΠ ΠžΠ’ΠžΠ‘ΠŸΠΠ›Π˜Π’Π•Π›Π¬ΠΠ«Π™ Π€Π•ΠΠžΠ’Π˜ΠŸ ΠœΠ•Π—Π•ΠΠ₯Π˜ΠœΠΠ›Π¬ΠΠ«Π₯ Π‘Π’Π’ΠžΠ›ΠžΠ’Π«Π₯ ΠšΠ›Π•Π’ΠžΠš: Π’Π›Π˜Π―ΠΠ˜Π• Π˜ΠœΠœΠ£ΠΠžΠœΠžΠ”Π£Π›Π―Π’ΠžΠ ΠžΠ’

    Get PDF
    In case of mycobacterial infection the granulomatous infiltration foci contain the significant amount of mesenchymal stem cells (MSC), which functional phenotype and respective function in anti-tuberculosis immune defense remain unknown.Goal of the study: to characterize the MSC phenotype, formed by their interaction with BCG of M. bovis and to evaluate the changes in this phenotype caused by the action of inhibitors and stimulants of immune regulatory action.Materials and methods: MSC retrieved from bone marrow of mice were cultured with the presence and absence of BCG of M. bovis and/or poludanum TLR3 agonist; and the effect of two latter on the production of pro- and anti-inflammatory cytokines was evaluated by enzyme multiplied immunoassay. Flow cytometry and radioactive testing were used to evaluate the impact of cultured BCG fluid and poludanum-conditioned MSC on the proliferative and apoptotic activity of splenocytes. The inhibitors of indoleamine 2,3-dioxygenase (IDO), cyclooxygenase-2 (COG-2) or NO synthase were added to certain cultures alone with BCG and poludanum, and the contributions of IDO, COG-2 and NO to BCG and poludanum-induced response were assessed.Results. Pro-inflammatory polarization of MSC under the action of BCG and poludanum was demonstrated. Pro-inflammatory MSC phenotype correlated to their anti-apoptogenic and growth-stimulating actions on the splenocytes. It was demonstrated that IDO and NO restrained BCG-induced polarization and conversely COG-2 promoted BCG-induced pro-inflammatory polarization of MSC.Conclusions. 1. MSC actively participate in the formation of immunologic anti-mycobacterial resistance. 2. Targeted regulation of IDO and NO production can be feasibly applied for formation of anti-tuberculous vaccinal immunity and control mycobacterial infection.Β ΠŸΡ€ΠΈ ΠΌΠΈΠΊΠΎΠ±Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ Π² ΠΎΡ‡Π°Π³Π°Ρ… Π³Ρ€Π°Π½ΡƒΠ»Π΅ΠΌΠ°Ρ‚ΠΎΠ·Π½ΠΎΠΉ ΠΈΠ½Ρ„ΠΈΠ»ΡŒΡ‚Ρ€Π°Ρ†ΠΈΠΈ содСрТится большоС количСство ΠΌΠ΅Π·Π΅Π½Ρ…ΠΈΠΌΠ°Π»ΡŒΠ½Ρ‹Ρ… стволовых ΠΊΠ»Π΅Ρ‚ΠΎΠΊ (МБК), Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΎΠ½Π°Π»ΡŒΠ½Ρ‹ΠΉ Ρ„Π΅Π½ΠΎΡ‚ΠΈΠΏ ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… ΠΈ, соотвСтствСнно, функция Π² ΠΏΡ€ΠΎΡ‚ΠΈΠ²ΠΎΡ‚ΡƒΠ±Π΅Ρ€ΠΊΡƒΠ»Π΅Π·Π½ΠΎΠΌ ΠΈΠΌΠΌΡƒΠ½ΠΈΡ‚Π΅Ρ‚Π΅ нСизвСстны.ЦСль исслСдования: ΠΎΡ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ·ΠΎΠ²Π°Ρ‚ΡŒ Ρ„Π΅Π½ΠΎΡ‚ΠΈΠΏ МБК, Ρ„ΠΎΡ€ΠΌΠΈΡ€ΡƒΡŽΡ‰ΠΈΠΉΡΡ ΠΏΡ€ΠΈ ΠΈΡ… взаимодСйствии с M. bovis Π‘Π¦Π–, ΠΈ ΠΎΡ†Π΅Π½ΠΈΡ‚ΡŒ измСнСния этого Ρ„Π΅Π½ΠΎΡ‚ΠΈΠΏΠ° ΠΏΠΎΠ΄ дСйствиСм ΠΈΠ½Π³ΠΈΠ±ΠΈΡ‚ΠΎΡ€ΠΎΠ² ΠΈ стимуляторов иммунорСгуляторной активности.ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹: МБК, ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½Π½Ρ‹Π΅ ΠΈΠ· костного ΠΌΠΎΠ·Π³Π° ΠΌΡ‹ΡˆΠ΅ΠΉ, ΠΊΡƒΠ»ΡŒΡ‚ΠΈΠ²ΠΈΡ€ΠΎΠ²Π°Π»ΠΈ Π² присутствии ΠΈΠ»ΠΈ отсутствии M. bovis Π‘Π¦Π– ΠΈ/ΠΈΠ»ΠΈ агониста TLR3 ΠΏΠΎΠ»ΡƒΠ΄Π°Π½Π° ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Π°ΠΌΠΈ ΠΈΠΌΠΌΡƒΠ½ΠΎΡ„Π΅Ρ€ΠΌΠ΅Π½Ρ‚Π½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ влияниС послСдних Π½Π° ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΡŽ ΠΏΡ€ΠΎ- ΠΈ Π°Π½Ρ‚ΠΈΠ²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… Ρ†ΠΈΡ‚ΠΎΠΊΠΈΠ½ΠΎΠ². ΠœΠ΅Ρ‚ΠΎΠ΄Π°ΠΌΠΈ ΠΏΡ€ΠΎΡ‚ΠΎΡ‡Π½ΠΎΠΉ Ρ†ΠΈΡ‚ΠΎΠΌΠ΅Ρ‚Ρ€ΠΈΠΈ ΠΈ Ρ€Π°Π΄ΠΈΠΎΠ°ΠΊΡ‚ΠΈΠ²Π½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ влияниС ΠΊΡƒΠ»ΡŒΡ‚ΡƒΡ€Π°Π»ΡŒΠ½ΠΎΠΉ Тидкости Π‘Π¦Π–- ΠΈ ΠΏΠΎΠ»ΡƒΠ΄Π°Π½-ΠΊΠΎΠ½Π΄ΠΈΡ†ΠΈΠΎΠ½ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Ρ… МБК Π½Π° ΠΏΡ€ΠΎΠ»ΠΈΡ„Π΅Ρ€Π°Ρ‚ΠΈΠ²Π½ΡƒΡŽ ΠΈ Π°ΠΏΠΎΠΏΡ‚ΠΎΡ‚ΠΈΡ‡Π΅ΡΠΊΡƒΡŽ Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ сплСноцитов. Π’ Ρ‡Π°ΡΡ‚ΡŒ ΠΊΡƒΠ»ΡŒΡ‚ΡƒΡ€ вмСстС с Π‘Π¦Π– ΠΈΠ»ΠΈ ΠΏΠΎΠ»ΡƒΠ΄Π°Π½ΠΎΠΌ добавляли ΠΈΠ½Π³ΠΈΠ±ΠΈΡ‚ΠΎΡ€Ρ‹ ΠΈΠ½Π΄ΠΎΠ»Π°ΠΌΠΈΠ½-2,3-диоксигСназы (Π˜Π”Πž), циклооксигСназы-2 (Π¦ΠžΠ“-2) ΠΈΠ»ΠΈ NO синтазы ΠΈ ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ Π²ΠΊΠ»Π°Π΄ Π˜Π”Πž, Π¦ΠžΠ“-2 ΠΈ NO Π² Π‘Π¦Π–- ΠΈ ΠΏΠΎΠ»ΡƒΠ΄Π°Π½-ΠΈΠ½Π΄ΡƒΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹ΠΉ ΠΎΡ‚Π²Π΅Ρ‚.Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Показана ΠΏΡ€ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½Π°Ρ поляризация МБК ΠΏΠΎΠ΄ дСйствиСм Π‘Π¦Π– ΠΈ ΠΏΠΎΠ»ΡƒΠ΄Π°Π½Π°. ΠŸΡ€ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΉ Ρ„Π΅Π½ΠΎΡ‚ΠΈΠΏ МБК ΠΊΠΎΡ€Ρ€Π΅Π»ΠΈΡ€ΠΎΠ²Π°Π» с ΠΈΡ… Π°Π½Ρ‚ΠΈΠ°ΠΏΠΎΠΏΡ‚ΠΎΠ³Π΅Π½Π½ΠΎΠΉ ΠΈ Ρ€ΠΎΡΡ‚ΠΎΡΡ‚ΠΈΠΌΡƒΠ»ΠΈΡ€ΡƒΡŽΡ‰Π΅ΠΉ Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒΡŽ ΠΏΠΎ ΠΎΡ‚Π½ΠΎΡˆΠ΅Π½ΠΈΡŽ ΠΊ сплСноцитам. ΠŸΡ€ΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡ‚Ρ€ΠΈΡ€ΠΎΠ²Π°Π½ΠΎ, Ρ‡Ρ‚ΠΎ Π˜Π”Πž ΠΈ NO ΡΠ΄Π΅Ρ€ΠΆΠΈΠ²Π°ΡŽΡ‚ Π‘Π¦Π–-ΠΈΠ½Π΄ΡƒΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π½ΡƒΡŽ ΠΏΠΎΠ»ΡΡ€ΠΈΠ·Π°Ρ†ΠΈΡŽ, Π° Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ Π¦ΠžΠ“-2, Π½Π°ΠΎΠ±ΠΎΡ€ΠΎΡ‚, способствуСт Π‘Π¦Π–-ΠΈΠ½Π΄ΡƒΡ†ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΏΡ€ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠΉ поляризации МБК.Π’Ρ‹Π²ΠΎΠ΄Ρ‹. 1. МБК ΡΠ²Π»ΡΡŽΡ‚ΡΡ Π°ΠΊΡ‚ΠΈΠ²Π½Ρ‹ΠΌΠΈ участники формирования иммунологичСской Π°Π½Ρ‚ΠΈΠΌΠΈΠΊΠΎΠ±Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ рСзистСнтности. 2. Π’Π°Ρ€Π³Π΅Ρ‚Π½ΠΎΠ΅ Ρ€Π΅Π³ΡƒΠ»ΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡ€ΠΎΠ΄ΡƒΠΊΡ†ΠΈΠΈ Π˜Π”Πž ΠΈ оксида Π°Π·ΠΎΡ‚Π° ΠΌΠΎΠΆΠ΅Ρ‚ Π±Ρ‹Ρ‚ΡŒ цСлСсообразно для формирования ΠΏΡ€ΠΎΡ‚ΠΈΠ²ΠΎΡ‚ΡƒΠ±Π΅Ρ€ΠΊΡƒΠ»Π΅Π·Π½ΠΎΠ³ΠΎ Π²Π°ΠΊΡ†ΠΈΠ½Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡƒΠ½ΠΈΡ‚Π΅Ρ‚Π° ΠΈ для Π±ΠΎΡ€ΡŒΠ±Ρ‹ с ΠΌΠΈΠΊΠΎΠ±Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠ΅ΠΉ

    Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

    Get PDF
    IMPORTANCE: Secretory phospholipase A2(sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. OBJECTIVE: To determine the effects of sPLA2inhibition with varespladib on cardiovascular outcomes. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). INTERVENTIONS: Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. MAIN OUTCOMES AND MEASURES: The primary efficacy measurewas a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. RESULTS: At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95%CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95%CI, 1.16-2.39; log-rank P = .005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). CONCLUSIONS AND RELEVANCE: In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130246. Copyright 2014 American Medical Association. All rights reserved

    Клинико-морфологичСскиС Π²Π°Ρ€ΠΈΠ°Π½Ρ‚Ρ‹ Π΄Π΅Π±ΡŽΡ‚Π° Π³Π΅ΠΏΠ°Ρ‚ΠΈΡ‚ΠΎΠ² ΠΏΡ€ΠΈ Π²Ρ€ΠΎΠΆΠ΄Ρ‘Π½Π½ΠΎΠΉ цитомСгаловирусной ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ ΠΈ Π³Π΅ΠΏΠ°Ρ‚ΠΈΡ‚Π΅ Π‘

    Get PDF
    We present comparative analysis of clinical – morphological data from infants with congenital cytomegalovirusΒ and hepatitis C infection. 97 patients with hepatitis underwentΒ a standard set of clinical and laboratory tests. ELISAΒ and PCR were used to verify infectious agents. Informed consentΒ to perform a liver biopsy was obtained from the parentsΒ of 28 children. immunohistochemical test of the liver samplesΒ managed to identify markers of cytomegalovirus (proteinΒ pp65 and p52) and hepatitis C (helicase NS3). The hepatitis CΒ virus was detected in 41 patients: 3a genotype – 68.3%, 1b –31.7% respectively. Congenital hepatitis C onset presentsΒ itself as mild and atypical and causes chronic hepatitis withΒ the 1st degree fibrosis. Cytomegalovirus replication markersΒ were found in 56 children. The most common manifestationsΒ of hepatitis associated with cytomegalovirus infection areΒ prolonged jaundice, cholestasis, gepatolienalny syndrome,Β early onset of the disease with increased transaminase levelsΒ and dominance in AST. Structural changes of the liver areΒ characterized by the presence of inflammatory infiltration,Β cholestasis with duktulopenia, lobular structure damage.Β Congenital cytomegalovirus-related hepatitis is likely to resultΒ in liver cirrhosis and is associated with poor prognosis.ΠŸΡ€Π΅Π΄ΡΡ‚Π°Π²Π»Π΅Π½ ΡΡ€Π°Π²Π½ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΉ Π°Π½Π°Π»ΠΈΠ·Β ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-морфологичСских Π΄Π°Π½Π½Ρ‹Ρ… Ρƒ Π΄Π΅Ρ‚Π΅ΠΉ ΠΏΠ΅Ρ€Π²ΠΎΠ³ΠΎ Π³ΠΎΠ΄Π°Β ΠΆΠΈΠ·Π½ΠΈ с Π²Ρ€ΠΎΠΆΠ΄Π΅Π½Π½Ρ‹ΠΌ Π³Π΅ΠΏΠ°Ρ‚ΠΈΡ‚ΠΎΠΌ Π‘ ΠΈ цитомСгаловирусной ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠ΅ΠΉ. Π£ 97 Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… Π³Π΅ΠΏΠ°Ρ‚ΠΈΡ‚ΠΎΠΌ примСнён стандартный комплСкс клиничСских ΠΈ лабораторных исслСдований, вСрификация ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΎΠ½Π½Ρ‹Ρ… Π°Π³Π΅Π½Ρ‚ΠΎΠ² ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½Π° ΠΌΠ΅Ρ‚ΠΎΠ΄Π°ΠΌΠΈ ИЀА ΠΈ ПЦР-диагностики. Π Π°Π·Ρ€Π΅ΡˆΠ΅Π½ΠΈΠ΅Β Π½Π° ΠΏΡ€ΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ биопсии ΠΏΠ΅Ρ‡Π΅Π½ΠΈ ΠΏΠΎΠ»ΡƒΡ‡Π΅Π½ΠΎ Ρƒ Ρ€ΠΎΠ΄ΠΈΡ‚Π΅Π»Π΅ΠΉΒ 28 Π΄Π΅Ρ‚Π΅ΠΉ. Π’ Π³Π΅ΠΏΠ°Ρ‚ΠΎΠ±ΠΈΠΎΠΏΡ‚Π°Ρ‚Π°Ρ… ΠΌΠ΅Ρ‚ΠΎΠ΄ΠΎΠΌ иммуногистохимии ΠΈΠ΄Π΅Π½Ρ‚ΠΈΡ„ΠΈΡ†ΠΈΡ€ΠΎΠ²Π°Π½Ρ‹ ΠΌΠ°Ρ€ΠΊΡ‘Ρ€Ρ‹ цитомСгаловирусной ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ (Π±Π΅Π»ΠΎΠΊ pp65 ΠΈ p52) ΠΈ Π³Π΅ΠΏΠ°Ρ‚ΠΈΡ‚Π° Π‘ (Ρ…Π΅Π»ΠΈΠΊΠ°Π·Π°Β NS3). Вирус Π³Π΅ΠΏΠ°Ρ‚ΠΈΡ‚Π° Π‘ выявлСн Ρƒ 41 Ρ€Π΅Π±Ρ‘Π½ΠΊΠ°: 3Π° Π³Π΅Π½ΠΎΡ‚ΠΈΠΏ – 68,3%, 1Π² – 31,7%. Π’Ρ€ΠΎΠΆΠ΄Ρ‘Π½Π½Ρ‹ΠΉ Π³Π΅ΠΏΠ°Ρ‚ΠΈΡ‚ Π‘ Π΄Π΅Π±ΡŽΡ‚ΠΈΡ€ΡƒΠ΅Ρ‚ Π² Π°Ρ‚ΠΈΠΏΠΈΡ‡Π½ΠΎΠΉ Π»Ρ‘Π³ΠΊΠΎΠΉ Ρ„ΠΎΡ€ΠΌΠ΅ ΠΈ Ρ„ΠΎΡ€ΠΌΠΈΡ€ΡƒΠ΅Ρ‚ хроничСский Π³Π΅ΠΏΠ°Ρ‚ΠΈΡ‚ с Ρ„ΠΈΠ±Ρ€ΠΎΠ·ΠΎΠΌ 1 стСпСни. ΠœΠ°Ρ€ΠΊΡ‘Ρ€Ρ‹ Ρ€Π΅ΠΏΠ»ΠΈΠΊΠ°Ρ†ΠΈΠΈ цитомСгаловируса ΠΎΠ±Π½Π°Ρ€ΡƒΠΆΠ΅Π½Ρ‹ Ρƒ 56 Π΄Π΅Ρ‚Π΅ΠΉ. Β«Π’ΠΈΠ·ΠΈΡ‚Π½ΠΎΠΉ ΠΊΠ°Ρ€Ρ‚ΠΎΡ‡ΠΊΠΎΠΉΒ» Π³Π΅ΠΏΠ°Ρ‚ΠΈΡ‚Π° ΠΏΡ€ΠΈ цитомСгаловирусной инфСкции являСтся затяТная ΠΆΠ΅Π»Ρ‚ΡƒΡ…Π°, холСстаз, Π³Π΅ΠΏΠ°Ρ‚ΠΎΠ»ΠΈΠ΅Π½Π°Π»ΡŒΠ½Ρ‹ΠΉ синдром, Ρ€Π°Π½Π½ΠΈΠΉ Π΄Π΅Π±ΡŽΡ‚ Π±ΠΎΠ»Π΅Π·Π½ΠΈ с ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½ΠΈΠ΅ΠΌ уровня трансаминаз ΠΈ Π΄ΠΎΠΌΠΈΠ½ΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ уровня АсАВ. Π‘Ρ‚Ρ€ΡƒΠΊΡ‚ΡƒΡ€Π½Ρ‹Π΅ измСнСния ΠΏΠ΅Ρ‡Π΅Π½ΠΈ Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ·ΡƒΡŽΡ‚ΡΡ Π½Π°Π»ΠΈΡ‡ΠΈΠ΅ΠΌ Π²ΠΎΡΠΏΠ°Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠΉ ΠΈΠ½Ρ„ΠΈΠ»ΡŒΡ‚Ρ€Π°Ρ†ΠΈΠΈ, холСстаза с ΠΏΡ€ΠΈΠ·Π½Π°ΠΊΠ°ΠΌΠΈ Π΄ΡƒΠΊΡ‚ΡƒΠ»ΠΎΠΏΠ΅Π½ΠΈΠΈ, Π½Π°Ρ€ΡƒΡˆΠ΅Π½ΠΈΠ΅ΠΌ Π΄ΠΎΠ»ΡŒΠΊΠΎΠ²ΠΎΠ³ΠΎΒ ΡΡ‚Ρ€ΠΎΠ΅Π½ΠΈΡ. ΠŸΡ€ΠΈ Π²Ρ€ΠΎΠΆΠ΄Ρ‘Π½Π½ΠΎΠΌ цитомСгаловирусном Π³Π΅ΠΏΠ°Ρ‚ΠΈΡ‚Π΅ высока Π²Π΅Ρ€ΠΎΡΡ‚Π½ΠΎΡΡ‚ΡŒ исхода заболСвания Π² Ρ†ΠΈΡ€Ρ€ΠΎΠ·Β ΠΏΠ΅Ρ‡Π΅Π½ΠΈ ΠΈ нСблагоприятный ΠΏΡ€ΠΎΠ³Π½ΠΎΠ·

    Eradication of Metastatic Renal Cell Carcinoma after Adenovirus-Encoded TNF-Related Apoptosis-Inducing Ligand (TRAIL)/CpG Immunotherapy

    Get PDF
    Despite evidence that antitumor immunity can be protective against renal cell carcinoma (RCC), few patients respond objectively to immunotherapy and the disease is fatal once metastases develop. We asked to what extent combinatorial immunotherapy with Adenovirus-encoded murine TNF-related apoptosis-inducing ligand (Ad5mTRAIL) plus CpG oligonucleotide, given at the primary tumor site, would prove efficacious against metastatic murine RCC. To quantitate primary renal and metastatic tumor growth in mice, we developed a luciferase-expressing Renca cell line, and monitored tumor burdens via bioluminescent imaging. Orthotopic tumor challenge gave rise to aggressive primary tumors and lung metastases that were detectable by day 7. Intra-renal administration of Ad5mTRAIL+CpG on day 7 led to an influx of effector phenotype CD4 and CD8 T cells into the kidney by day 12 and regression of established primary renal tumors. Intra-renal immunotherapy also led to systemic immune responses characterized by splenomegaly, elevated serum IgG levels, increased CD4 and CD8 T cell infiltration into the lungs, and elimination of metastatic lung tumors. Tumor regression was primarily dependent upon CD8 T cells and resulted in prolonged survival of treated mice. Thus, local administration of Ad5mTRAIL+CpG at the primary tumor site can initiate CD8-dependent systemic immunity that is sufficient to cause regression of metastatic lung tumors. A similar approach may prove beneficial for patients with metastatic RCC

    Phase transition in Random Circuit Sampling

    Full text link
    Quantum computers hold the promise of executing tasks beyond the capability of classical computers. Noise competes with coherent evolution and destroys long-range correlations, making it an outstanding challenge to fully leverage the computation power of near-term quantum processors. We report Random Circuit Sampling (RCS) experiments where we identify distinct phases driven by the interplay between quantum dynamics and noise. Using cross-entropy benchmarking, we observe phase boundaries which can define the computational complexity of noisy quantum evolution. We conclude by presenting an RCS experiment with 70 qubits at 24 cycles. We estimate the computational cost against improved classical methods and demonstrate that our experiment is beyond the capabilities of existing classical supercomputers
    • …
    corecore